Drug Profile
Research programme: mitochondrial angiotensin receptor antagonists - Gemstone Biotherapeutics
Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator Johns Hopkins University
- Developer Gemstone Biotherapeutics; NYU Winthrop Hospital
- Class
- Mechanism of Action Angiotensin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diabetic foot ulcer
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Diabetic foot ulcer in USA (Topical)
- 28 Mar 2020 No recent reports of development identified for preclinical development in Diabetic-foot-ulcer in USA (Topical)